These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 16779757)

  • 21. [Treatment of community-acquired pneumonia--treatment].
    Andersen LV; Brock B; Jakobsen P; Nielsen LP
    Ugeskr Laeger; 2008 Jan; 170(3):127-30. PubMed ID: 18208726
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The problem of early mortality in pneumococcal pneumonia: a study of risk factors.
    Burgos J; Luján M; Larrosa MN; Pedro-Botet ML; Fontanals D; Quesada MD; Lung M; Bermudo G; Almirante B; Falcó V
    Eur Respir J; 2015 Aug; 46(2):561-4. PubMed ID: 26022957
    [No Abstract]   [Full Text] [Related]  

  • 23. Historical and regulatory perspectives on the treatment effect of antibacterial drugs for community-acquired pneumonia.
    Singer M; Nambiar S; Valappil T; Higgins K; Gitterman S
    Clin Infect Dis; 2008 Dec; 47 Suppl 3():S216-24. PubMed ID: 18986293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Penicillin for Pneumococcal Pneumonia.
    Manu P; Rogozea L
    Am J Ther; 2016; 23(2):e326-7. PubMed ID: 26950586
    [No Abstract]   [Full Text] [Related]  

  • 25. Cefuroxime for empiric treatment of community-acquired pneumococcal pneumonia: is there a generation gap?
    Wiener-Well Y; Raveh D; Schlesinger Y; Yinnon AM; Rudensky B
    Chemotherapy; 2009; 55(2):97-104. PubMed ID: 19145079
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiology of invasive pneumococcal disease in Kumasi, Ghana.
    Holliman RE; Liddy H; Johnson JD; Adjei O
    Trans R Soc Trop Med Hyg; 2007 Apr; 101(4):405-13. PubMed ID: 17126867
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Penicillin-resistant pneumococci and community-acquired pneumonia.
    Sánchez C; Armengol R; Lite J; Mir I; Garau J
    Lancet; 1992 Apr; 339(8799):988. PubMed ID: 1348814
    [No Abstract]   [Full Text] [Related]  

  • 28. [Empyema: bacterial epidemiology and antibiotic resistance].
    Vu-Thien H
    Arch Pediatr; 2008 Oct; 15 Suppl 2():S81-3. PubMed ID: 19000860
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bactericidal efficacy of ABI-0043, a novel rifamycin, in a murine pneumococcal pneumonia model.
    Lee SY; Tessier PR; Murphy CK; Nicolau DP
    J Antibiot (Tokyo); 2006 Dec; 59(12):804-7. PubMed ID: 17323649
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Severe community-acquired pneumococcal pneumonia -- what might be done better.
    Ewig S; Torres A
    Intensive Care Med; 1999 Feb; 25(2):143-5. PubMed ID: 10193539
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment of lobar pneumonia in out-patients.
    Sibellas M
    J Trop Med Hyg; 1966 Apr; 69(4):94-6. PubMed ID: 5909940
    [No Abstract]   [Full Text] [Related]  

  • 32. [Fatal outcome of pneumococcal pneumonia and following conclusions].
    Møller NE
    Ugeskr Laeger; 2004 Jun; 166(25):2476-7. PubMed ID: 15283121
    [No Abstract]   [Full Text] [Related]  

  • 33. Supportive treatment of adult lobar pneumonia.
    Pearson CA
    Trop Doct; 1991 Jul; 21(3):120-1. PubMed ID: 1926552
    [No Abstract]   [Full Text] [Related]  

  • 34. [Penicillin G use in pneumococcal pneumonia treatment].
    Mella S; Blamey R; Riedel G; Aylwin M; Chabouty H
    Rev Chilena Infectol; 2005 Dec; 22(4):377-8. PubMed ID: 16341361
    [No Abstract]   [Full Text] [Related]  

  • 35. [In vitro resistance rates of Streptococcus pneumoniae and Haemophilus influenzae clinical isolates to the antibiotics used in therapy].
    Uncu H; Colakoğlu S; Turunç T; Demiroğlu YZ; Arslan H
    Mikrobiyol Bul; 2007 Jul; 41(3):441-6. PubMed ID: 17933256
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does antibiotic selection impact patient outcome?
    Harbarth S; Nobre V; Pittet D
    Clin Infect Dis; 2007 Jan; 44(1):87-93. PubMed ID: 17143822
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A clinical approach to the choice of antimicrobial agents.
    Wunderlich HF; Raff MJ; Melo JC
    J Ky Med Assoc; 1979 Jan; 77(1):11-2. PubMed ID: 759531
    [No Abstract]   [Full Text] [Related]  

  • 38. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance.
    Weinstein MP; Klugman KP; Jones RN
    Clin Infect Dis; 2009 Jun; 48(11):1596-600. PubMed ID: 19400744
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lobar pneumonia and alcoholism: an analysis of thirty-seven cases.
    Chomet B; Gach BM
    Am J Med Sci; 1967 Mar; 253(3):300-4. PubMed ID: 6021690
    [No Abstract]   [Full Text] [Related]  

  • 40. Amoxicillin versus sparfloxacin in the treatment of presumed pneumococcal pneumonia.
    Johnson JR
    Clin Infect Dis; 2000 Jan; 30(1):234-5. PubMed ID: 10619776
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.